<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920422</url>
  </required_header>
  <id_info>
    <org_study_id>21749</org_study_id>
    <nct_id>NCT04920422</nct_id>
  </id_info>
  <brief_title>RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.</brief_title>
  <acronym>RE-SEARCH</acronym>
  <official_title>Dosing Patterns With Regorafenib in Clinical Practice in Spain: A Retrospective Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are collecting more information to improve treatment of metastatic colorectal&#xD;
      cancer (mCRC) with regorafenib.&#xD;
&#xD;
      Metastatic colorectal cancer (mCRC) is a cancer that starts in the large bowel and involves&#xD;
      the rectum (the lowest part of the gut) and has spread to other parts of the body.&#xD;
      Regorafenib is available to treat patients with mCRC that have previously been treated with,&#xD;
      or are not considered candidates for, available therapies. It is an anti-cancer drug that&#xD;
      blocks several proteins called enzymes which are involved in the growth of cancer. It is&#xD;
      known that doctors may change the amount (the dose) of regorafenib they give, so that the&#xD;
      patients better tolerate the treatment. Little information is however available on the doses&#xD;
      of regorafenib given in Spain in usual practice.&#xD;
&#xD;
      In this study researchers want to learn how and in which amount regorafenib is usually given&#xD;
      to patients with mCRC in Spain. They aim to identify the starting dose of regorafenib and to&#xD;
      describe dosing patterns during the first two four-week treatment periods (cycles) according&#xD;
      to usual clinical practice.&#xD;
&#xD;
      To answer these questions, the researchers will look back at cases that have already happened&#xD;
      when the study begins. Medical history data from the day of diagnosis of the mCRC until the&#xD;
      day prior to the inclusion in the study is collected from the medical records of adult&#xD;
      patients with mCRC. All patients must have started their treatment with regorafenib since&#xD;
      January 2017 and have taken regorafenib for at least 3 months.&#xD;
&#xD;
      The researchers will collect the information between around June 2021 until around November&#xD;
      2021. The final report is planned to be available in July 2022.&#xD;
&#xD;
      No investigational products will be administered in this study. Moreover, no additional&#xD;
      visits or laboratory tests will be performed apart from the usual tests/treatments done in&#xD;
      usual practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients that start regorafenib treatment with a dose of 80 mg.</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients that start regorafenib treatment with a dose of 120 mg</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients that start regorafenib treatment with a dose of 160 mg</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients that follow each dosing patterns during first two cycles of treatment</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median number of previous lines of treatment received for metastatic colorectal cancer (mCRC) at index.</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At index (at regorafenib start date)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients according to number of previous lines received at index.</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At index (at regorafenib start date)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time from mCRC diagnosis</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At index (at regorafenib start date)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of metastatic locations</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At index (at regorafenib start date)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ECOG performance status at index</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>ECOG: Eastern Cooperative Oncology Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with comorbidities at index.</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At index (at regorafenib start date)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with mutated BRAF status at index</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At index (at regorafenib start date)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with mutated KRAS status at index.</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At index (at regorafenib start date)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of regorafenib treatment (cycles)</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression free survival</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients for each reason of dose modification.</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
    <description>At follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that start cycle 3 based on dosing patterns.</measure>
    <time_frame>Retrospective data analysis from January 2017 to at least 3 months prior to being included in the study.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">242</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic colorectal cancer patients.</arm_group_label>
    <description>Medical history data of all patients with at least 1 treatment with regorafenib will be collected retrospectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Retrospective analysis using database without any intervention assigned in the study.</description>
    <arm_group_label>Metastatic colorectal cancer patients.</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Spanish participants will be included in this study if they had at least one dose of&#xD;
        regorafenib in past treatment cycle.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient â‰¥ 18 years&#xD;
&#xD;
          -  Patients with histological confirmation of mCRC&#xD;
&#xD;
          -  Patient who started treatment with regorafenib for mCRC according to usual clinical&#xD;
             practice during or after January 2017 and at least 3 months prior to the inclusion in&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who have been treated with regorafenib during their participation in a&#xD;
             clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Many Locations</name>
      <address>
        <city>Multiple Locations</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal cancer</keyword>
  <keyword>Refractory metastatic colorectal cancer</keyword>
  <keyword>Observational Study</keyword>
  <keyword>Regorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access.&#xD;
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.&#xD;
Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

